Fundación Jimenez Diaz de Madrid Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2020
NCT04392531
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Carmen Gonzalez Enguita | FUNDACION JIMENEZ DIAZ | Fundación Jimenez Diaz de Madrid

Active Ingredients

Drugs in Phase 4 Trials (1)

cyclosporine (sandimmune) (1 trial)

Drugs in Other Trials (1)

bupivacaine (Exparel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2